Now is the best time for community pharmacy to integrate its model of NHS representation and support to ensure better outcomes for contractors, said James Wood, director of Contractor & LPC Support, Pharmaceutical Services Negotiating Committee (PSNC).
It is important for the sector to adapt to the new landscape and address challenges such as workforce, digital data, integration of pharmacy services, and medicines optimisation, he said during the first session of the sixth annual Pharmacy Business Conference held online on Tuesday, September 21.
Under the new system, every part of England will be covered by integrated care systems (ICSs) from April 2022. ICSs have been created to bring about big changes in how health and care services in England are planned, paid for and delivered. They are a key part of the direction of travel for the NHS as outlined in the NHS Long Term Plan.
In his maiden speech delivered to community pharmacy since becoming new minister with responsibility for the sector, Will Quince MP said he's determined to be
"your champion" and "voice in government".
Addressing delegates on Wednesday (Oct 12) as chief guest at the 22nd Pharmacy Business Awards in central London, he praised community pharmacy for delivering 25
million Covid-19 vaccines, five million flu jabs, 200 million lateral flow testing kits and millions of medicines throughout the pandemic.
"These local efforts became the national success story," he told over 600 attendees at a gala dinner held at the iconic Park Plaza Westminster Bridge hotel
overlooking the Houses of Parliament.
'We need you now'
Quince, who was appointed minister of state at the Department of Health and Social Care on 7 September 2022, added: "Just as we needed you in the pandemic, we
need you now," highlighting the vital role of community pharmacy in realising the secretary of state (Thérèse Coffey)'s vision, particularly in regard to her
much talked about 'Plan for Patients'.
Pharmacists, politicians, faith and community leaders paid tribute to Parvatiben Solanki, the co-founder of the Asian Media Group (AMG), publishers of Pharmacy
Business magazine. Mrs Solanki passed away in London last Thursday (September 8). She was 86.
Along with her husband, the late Ramniklal Solanki CBE, Mrs Solanki played a key role in establishing AMG as one of Britain's largest Asian publishing houses.
They began the business in April 1968, producing the flagship title, Garavi Gujarat, from their terraced house in Wembley, north London.
Today AMG publishes a range of trade and consumer titles, including Pharmacy Business, Asian Trader, Garavi Gujarat and Eastern Eye, in addition to hosting gala
awards dinners. AMG has offices in the UK, US and India, and also publishes titles in the United States.
More than 9,300 pharmacy contractors would benefit from earlier advance payment in February, Pharmaceutical Services Negotiating Committee (PSNC) said in an update.
Contractors who declared their January 2022 FP34C submission figures through the Manage Your Service (MYS) portal by February 5 will receive earlier advance payments
by today (February 10).
The statistics indicates nearly 2,000 contractors will not receive any earlier advance payment this month, either because their January declarations were submitted late or they used the paper FP34C submission document to make their declaration, PSNC said.
These contractors will receive their advance payments in accordance with the normal payment timetable i.e. on March 1.
The negotiator reminded contractors that from April 2022 MYS will be the only process to make monthly submissions.
In partnership with the Prescription Charges Coalition (PCC), the Royal Pharmaceutical Society (RPS) has taken a significant step by urging political
leaders to abolish prescription charges for individuals with long-term conditions.
Tase Oputu, Chair of the RPS England Pharmacy Board, signed an open letter on Thursday, calling on party leaders to address this pressing issue.
The letter emphasises the outdated nature of the current exemption list, which forces individuals with chronic conditions like Parkinson's, cystic fibrosis,
and HIV to bear the cost of their essential medications.
It urges party leaders to urgently review and update the exemption list to ensure equitable access to necessary medicines.
"Nobody should face a financial barrier to accessing the medicines they need," Oputu stated.
New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a
standalone prescription medicine and vaccine business since carving out its consumer health division Haleon.
After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of
strong results.
The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy.
Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain
around U.S. litigation over heartburn drug Zantac.
Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.
The Royal Pharmaceutical Society (RPS) Wales has welcomed proposals from the Welsh government to increase access to PrEP via community pharmacies for people at
risk of HIV.
The new HIV Action Plan for Wales consultation proposes a shared care model between primary care and specialist sexual health services to improve access to PrEP.
Commenting on the proposal, chair of RPS in Wales Cheryl Way said: "Increasing access to the medicines has been a long-standing issue of concern for us at RPS and
we're therefore delighted to see the proposals outlined by the Welsh government to develop a model which will enable PrEP to be provided by community pharmacies
across Wales.
"PrEP are highly effective medicines, that reduce the chances of getting HIV, as proven by the Welsh Government's three year PrEPARED study which found no new
diagnoses of HIV among over 1,200 people taking PrEP in Wales. This is clear evidence that PrEP should be made as easily accessible as possible to those who need it.
A group of 21 community pharmacies in the Midlands and Yorkshire will have a new name - Pickfords Pharmacy.
The group has been created by combining three independent pharmacy businesses which traded as Mr Pickford's, McGills Pharmacy and D&R Sharp.
All pharmacies in the new group will be rebranded over the coming months, with a series of launch events planned by local teams.
Speaking after the unveiling of the first branch to receive new signage in Hexthorpe Doncaster, Mimi Lau, Pickfords Pharmacy's chief operating officer, said:
"This is a turning point for the group, with all our pharmacies operating under one name with a consistent, contemporary brand.
"Initial reaction has been fantastic and very soon the name Pickfords Pharmacy will be widely recognised for the great service we deliver to customers and patients
every day."
Speaking of the consolidation, Nick Yarrow, the newly appointed group chief executive officer, commented: "Since the enlarged group came together last year, we have
been striving to ensure that the best elements of each business have been retained for the benefit of our customers and team members.
"This is part of our journey to be more than just a pharmacy - we want to be a trusted source of healthcare services at the heart of each one of the communities we
serve".
The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments
to pharmacy services in England on Wednesday (26 April).
"They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments
across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said
DHSC.
Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never
been more important.
"The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets.
"In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers
of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce."
National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five
standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.
Two dozen parliamentarians from across the political spectrum have called on the prime minister to act as a wave of pharmacy closures in recent years has
threatened to spiral out of control.
A letter to the prime minister signed by 24 MPs and peers has warned that worse could be yet to come after "spiralling business costs" and "year after year of real
terms funding cuts" have led to hundreds of pharmacy closures.
New data from the PSNC shows that over 639 local pharmacies have been lost in England since 2016.
"This is the equivalent to just short of one pharmacy closure per constituency", the cross-party group warned.
The letter comes as MPs came together at a parliamentary summit to call for pharmacies to be embraced as a "game-changer" for tackling healthcare backlogs and taking
pressure off other areas of the NHS. A 'Future of Pharmacy' event was attended by 53 parliamentarians on July 5 in the Palace of Westminster.
At the event parliamentarians heard directly from frontline pharmacists and representatives of pharmacy bodies where a map of constituency-specific pharmacy numbers
was also unveiled, with details of the number of pharmacy closures in MPs' local area.
Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up
recruitment in studies conducted by drugmakers.
With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively
match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and
access to an extensive foundation of pharmacy and patient-authorised clinical data.
The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants,
the company will be able to reduce the time it takes to match eligible patients to clinical trials.
"Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive
solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer,
Walgreens.
There is a realistic possibility of large waves of Covid-19 infection in the future in Britain and such waves might even be considered likely, epidemiologists who model the Covid-19 pandemic to inform government advice have said.
Prime minister Boris Johnson has ditched legal restrictions in England, saying that, while the pandemic was not over, Britain needs to learn to live with Covid.
The Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) said the emergence of new viral variants was the biggest unknown factor in the medium-to-long term, along with waning population immunity and changes in mixing patterns.
"Large future waves of infection that need active management to prevent detrimental pressure on the health and care sector are, at least, a realistic possibility (high confidence) or likely (medium confidence)," SPI-M-O said in a consensus statement published on Friday.
AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company.
In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing
strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations,
and trading.
Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the
industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."
The Royal Pharmaceutical Society (RPS) has published its general election manifesto highlighting some of the key challenges the next Government will face to
support patients and the NHS.
The manifesto calls on general election candidates to show their support to securing patient access to medicines, a better-connected NHS, enhancing accessible
prescribing in local communities, and maximising health improvement through locally accessible pharmacy teams.
Candidates are urged to called on the next Government, if elected, to support the pharmacy workforce to deliver patient care, unlock the potential of new advances
in medicines, and continue to support funding for the UK science and research community.
The manifesto highlights the need for investment in IT infrastructure to support a better-connected NHS to enable all health professionals to access and update a
patient's record.
The General Pharmaceutical Council (GPhC) has published a new strategy pledging to deliver equality, improve diversity and foster inclusion in all aspects of its work.
The strategy was updated after a public consultation held between April and July. It's key themes are:
To make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias.
To use our standards to proactively help tackle discrimination and to make sure everyone can access person-centred care, fostering equality of health outcomes.To lead by example and demonstrate best practice within our organisation, holding ourselves to the same high standards we expect of others.
GPhC chair Nigel Clarke said having a strategy is vital as the pandemic has exposed "the scope and scale of inequities in society, in healthcare outcomes and in pharmacy."
"Inequality and exclusion are bad for people's health. Therefore, this strategy is fundamental to our core purpose as a regulator and our vision for safe and effective pharmacy care at the heart of healthier communities."
The ongoing pharmacist workforce crisis has posed a significant risk to patients' access to care, medicines and advice - particularly affecting the elderly and vulnerable living in areas with health inequalities.
Many from the sector have raised concerns about this issue with the Company Chemists' Association (CCA) recently acknowledging the shortage of pharmacists or pharmacy technicians in the country to meet the needs of patients and the NHS.
The trade body representing almost 50 per cent of the community pharmacy sector said that pharmacy teams are exhausted after working tirelessly during the pandemic,
adding that Covid, Brexit and NHS reforms have exacerbated the shortage.
Covid and winter-related sickness absences are adding to the strain and with Brexit it has become difficult to attract overseas pharmacists to the UK.
Britain on Monday (January 10) put the biggest private health companies on high alert to deliver crucial treatments such as cancer surgery should Omicron
overwhelm National Health Service hospitals in England.
The United Kingdom's death toll from the Covid-19 pandemic stands at 150,154, the world's seventh worst official Covid toll after the United States, Brazil, India, Russia, Mexico and Peru.
Prime minister Boris Johnson has bet on refraining from lockdowns to deal with the Omicron variant which in recent weeks has swept across the UK, albeit with death
rates significantly lower than previous waves.
In a sign of just how stretched the NHS could become, health secretary Sajid Javid ordered England's NHS to strike a three-month deal with private health companies to allow patients to get treatments such as cancer surgery outside.
"Millions of patients have already got their tests and treatment quicker thanks to our existing deal with independent providers," said David Sloman, NHS England chief operating officer and Covid incident director.
Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation
DACH Cluster.
van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and
Granu Fink.
He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter
& Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as
multifunctional Team Leader Emerging Channels.
The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General
Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several
business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner
Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.
Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market,
the German company's top executive Ugur Sahin told magazine Der Spiegel.
BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies
on and the locations where it will conduct the trials, Sahin said.
The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular
treatment for cancer patients.
"We believe that this should be possible for large amounts of patients before 2030," Sahin said.
Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that
contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims.
GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent.
GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent
listed company last month, comprises consumer health assets once partly owned by GSK.
The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus.
The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a
note.